Aligos Therapeutics (ALGS) AI Stock Analysis

• Market Cap: $34.67M
• Dividend Yield: N/A
• Average Volume (3M): 166.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: -76.29%
• EPS Growth: N/A
• Country: US
• Employees: 70
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -2.11
• Shares Outstanding: 5,314,801
• 10 Day Avg. Volume: 206,149
• 30 Day Avg. Volume: 166,528
• PEG Ratio: <0.01
• Price to Book (P/B): -2.47
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $53.00
• Price Target Upside: 834.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 45 Neutral
• Price Target: $5.50 ▼( -3.00% Downside)

Aligos Therapeutics currently faces significant profitability and cash flow challenges typical for early-stage biotechnology firms. Despite a strong equity position and low leverage, the negative financial metrics combined with bearish technical indicators make the stock less attractive at present. The valuation is hindered by the lack of profitability, resulting in a lower overall score.

Positive Factors

Clinical Milestones

The initiation of ALG-000184's randomized, double-blind, active-controlled Phase 2 study is regarded as Aligos' next major milestone.

Market Differentiation

ALG-000184 achieved the primary endpoint in 100% of patients in the Phase 1 study, compared to 21% for the standard-of-care treatment.

Therapeutic Potential

ALG-000184 showcased robust and sustained antiviral activity in both HBeAg-positive and HBeAg-negative patients with CHB, highlighting its potential as a first-line therapy for long-term viral suppression.

Negative Factors

Clinical Trial Risks

The success of ALG-000184's Phase 2 study hinges on achieving its registrational endpoint, introducing potential risks if the outcomes do not meet expectations.

Aligos Therapeutics Business Overview & Revenue Model

Company Description

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

How the Company Makes Money

Aligos Therapeutics generates revenue primarily through strategic partnerships, collaborations, and potential future sales of its drug candidates. The company may enter into licensing agreements with larger pharmaceutical companies, providing upfront payments, milestone payments, and royalties on sales. Aligos focuses on advancing its proprietary drug candidates through clinical trials, aiming to bring them to market for commercialization. As a clinical-stage company, it currently relies on funding from investors and partnerships to support its research and development activities. Successful development and approval of its drug candidates would eventually lead to revenue generation from product sales.

Aligos Therapeutics Financial Statement Overview

Summary

Aligos Therapeutics is experiencing severe financial difficulties characterized by zero revenue in 2024 and persistent losses. The negative equity position and ongoing cash flow challenges suggest significant financial instability. Strategic adjustments are necessary to improve financial health and address the ongoing operational and financial challenges.

Income Statement

Aligos Therapeutics has faced consistent challenges in generating revenue, with a significant drop to zero in 2024 from $15.53 million in 2023. The company remains unprofitable, experiencing negative net income consistently. The severe negative EBIT and EBITDA margins indicate ongoing operational challenges and lack of profitability.

Balance Sheet

The company's balance sheet shows significant financial distress, with negative stockholders' equity in 2024 indicating more liabilities than assets. The total debt has decreased slightly, but the negative equity undermines financial stability. The lack of equity cushion poses a risk to solvency.

Cash Flow

There is a negative trend in cash flow, with negative operating and free cash flow persisting. While operating cash flow slightly improved in 2024, overall cash flow metrics indicate a critical need for cash management improvements. Minimal investing and financing activities limit cash flow improvements.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.94M	15.53M	13.91M	4.36M	0.00
	Gross Profit
3.94M	12.46M	10.23M	-99.79M	-3.33M
	EBIT
-89.15M	-88.13M	-97.58M	-128.32M	-97.83M
	EBITDA
-89.15M	-85.06M	-93.91M	-124.54M	-105.06M
	Net Income Common Stockholders
-131.21M	-87.68M	-96.05M	-128.33M	-108.54M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
56.94M	135.70M	125.83M	190.73M	243.51M
	Total Assets
70.09M	151.53M	146.69M	235.37M	265.30M
	Total Debt
8.38M	11.14M	12.57M	14.46M	13.01M
	Net Debt
-28.62M	-124.57M	-68.77M	-172.36M	-207.38M
	Total Liabilities
99.07M	59.45M	42.79M	50.64M	45.26M
	Stockholders Equity
-28.97M	92.08M	103.90M	184.73M	220.04M
Cash Flow		Free Cash Flow
-80.87M	-79.02M	-80.33M	-116.55M	-76.33M
	Operating Cash Flow
-80.74M	-79.00M	-79.39M	-115.66M	-74.26M
	Investing Cash Flow
-18.28M	44.98M	-26.29M	3.02M	32.76M
	Financing Cash Flow
355.00K	88.33M	164.00K	78.68M	192.35M

Aligos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.67
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Neutral. The current price of 5.67 is above the 20-day moving average (MA) of 5.43, below the 50-day MA of 6.71, and below the 200-day MA of 16.19, indicating a neutral trend. The MACD of -0.29 indicates Negative momentum. The RSI at 46.91 is Neutral, neither overbought nor oversold. The STOCH value of 66.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALGS.

Aligos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TVRD	57 Neutral	$259.67M	―	-270.01%	―	-65.96%	40.80%
Sector *	53 Neutral	$5.14B	3.06	-43.57%	2.81%	16.81%	-0.12%
ALGS	45 Neutral	$34.67M	―	-60.44%	―	-76.29%	―
PYPD	41 Neutral	$28.43M	―	-853.05%	―	―	34.97%
GBIO	39 Underperform	$26.94M	―	-70.06%	―	146.47%	57.85%
ANVS	35 Underperform	$40.53M	―	-280.78%	―	―	68.75%
NRSN	30 Underperform	$35.02M	―	-2880.11%	―	―	31.09%

Aligos Therapeutics Corporate Events

Aligos Therapeutics Secures $105M in Private Placement

On February 11, 2025, Aligos Therapeutics entered into a Securities Purchase Agreement with investors for a private placement, expected to result in approximately $105 million in gross proceeds. This funding is anticipated to support the advancement of their ALG-000184 into a Phase 2 clinical study and extend the company’s cash runway into the second half of 2026. The private placement, led by a life sciences investment firm, involves the sale of common stock and warrants and is expected to close on February 13, 2025. This financial boost is a strategic move to solidify Aligos’s position in the biotechnology industry focused on liver and viral diseases, providing potential long-term benefits for stakeholders.